The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27823886 |
96 |
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling. |
The University of Queensland |
| 28103022 |
36 |
Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core. |
Vanderbilt University |
| 26986178 |
172 |
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance. |
Ferring Research Institute |
| 26895657 |
13 |
A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus. |
Peking University |
| 26352676 |
29 |
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. |
The University of Queensland |
| 26308095 |
138 |
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. |
Novo Nordisk |
| 25839426 |
36 |
Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. |
University of Queensland |
| 25127101 |
26 |
Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists. |
Dainippon Sumitomo Pharma |
| 25423411 |
28 |
Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). |
Vanderbilt University School of Medicine |
| 24527772 |
262 |
The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist. |
Merck Research Laboratories |
| 24044354 |
11 |
A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates. |
Tufts University |
| 23562063 |
32 |
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus. |
Pfizer |
| 22708876 |
106 |
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes. |
Merck Research Laboratories |
| 19597507 |
62 |
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. |
Indiana University |
| 19702274 |
31 |
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. |
Bristol-Myers Squibb |
| 17213325 |
4 |
Small-molecule agonists for the glucagon-like peptide 1 receptor. |
Novo Nordisk Als |
| 22119466 |
38 |
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity. |
Pfizer |
| 22030028 |
55 |
Discovery of N-aryl-2-acylindole human glucagon receptor antagonists. |
Merck Research Laboratories |
| 22001094 |
78 |
Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists. |
Merck Research Laboratories |
| 21147532 |
82 |
Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core. |
Merck Research Laboratories |
| 20687610 |
12 |
Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. |
University of Texas At Dallas |
| 20576431 |
1 |
Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution. |
Shionogi |
| 18952440 |
49 |
Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. |
University of Texas At Dallas |
| 18950150 |
16 |
Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1. |
Tufts University |
| 18707090 |
68 |
Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. |
Novo Nordisk |
| 18412318 |
42 |
Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. |
Amgen |
| 17827014 |
44 |
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. |
Pfizer |
| 17201415 |
47 |
New beta-alanine derivatives are orally available glucagon receptor antagonists. |
Novo Nordisk |
| 16102966 |
55 |
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. |
Merck Research Laboratories |
| 15357960 |
20 |
Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. |
Conjuchem |
| 10794683 |
36 |
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. |
Novo Nordisk |
| 31471103 |
6 |
Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties. |
China Pharmaceutical University |
| 31577440 |
4 |
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors. |
Sosei Heptares |
| 31494471 |
15 |
Natural dimers of coumarin, chalcones, and resveratrol and the link between structure and pharmacology. |
Nagasaki International University |
| 29939744 |
179 |
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. |
Shanghaitech University |
| 31596080 |
10 |
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). |
Sanofi-Aventis Deutschland |
| 31930920 |
69 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. |
Terns Pharmaceuticals |
| 24308627 |
19 |
Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates. |
China Pharmaceutical University |
| 29673717 |
8 |
Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity. |
China Pharmaceutical University |
| 29153547 |
50 |
Optimization of peptide-based polyagonists for treatment of diabetes and obesity. |
Novo Nordisk Research Center Indianapolis |
| 28772236 |
53 |
A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects. |
China Pharmaceutical University |
| 29879354 |
54 |
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations. |
Sanofi-Aventis Deutschland |
| 28448133 |
56 |
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. |
Sanofi-Aventis Deutschland |
| 28771355 |
11 |
Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues. |
University of Copenhagen |
Search and Browse
